doi: 10.1111/dom.15184
Hikma Pharmaceuticals Hikma is working on generic versions and biosimilars of GLP-1 drugs to improve accessibility and affordability in developing markets
Injectable semaglutide, administered subcutaneously once weekly, has a half-life of approximately one week and reaches steady-state concentrations after 4-5 weeks of treatment
GLP-1RAS AND DIABETIC RETINOPATHY The phenomenon of worsening diabetic retinopathy (DR), often termed rebound retinopathy, is a well-established, paradoxical retinal finding linked to improved blood glucose levels, typically observed 3 months to 3 years after intense glucose lowering
There appears to be a relationship between autoimmune thyroid disease and metabolic syndrome, with inflammation potentially playing a role, though more research is needed to fully understand these connections
Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism